Maternal exposure to SSRIs or SNRIs and the risk of congenital abnormalities in offspring: A systematic review and meta-analysis.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Serotonin and Noradrenaline Reuptake Inhibitors* ; Cardiovascular Abnormalities*/chemically induced; Female ; Humans ; Selective Serotonin Reuptake Inhibitors/adverse effects ; Maternal Exposure/adverse effects ; Norepinephrine ; Serotonin

Background: The association of maternal exposure to selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) with the risk of system-specific congenital malformations in offspring remains unclear. We conducted a meta-analysis to examine this association and the risk difference between these two types of inhibitors.
Methods: A literature search was performed from January 2000 to May 2023 using PubMed and Web of Science databases. Cohort and case-control studies that assess the association of maternal exposure to SSRIs or SNRIs with the risk of congenital abnormalities were eligible for the study.
Results: Twenty-one cohort studies and seven case-control studies were included in the meta-analysis. Compared to non-exposure, maternal exposure to SNRIs is associated with a higher risk of congenital cardiovascular abnormalities (pooled OR: 1.64 with 95% CI: 1.36, 1.97), anomalies of the kidney and urinary tract (pooled OR: 1.63 with 95% CI: 1.21, 2.20), malformations of nervous system (pooled OR: 2.28 with 95% CI: 1.50, 3.45), anomalies of digestive system (pooled OR: 2.05 with 95% CI: 1.60, 2.64) and abdominal birth defects (pooled OR: 2.91 with 95%CI: 1.98, 4.28), while maternal exposure to SSRIs is associated with a higher risk of congenital cardiovascular abnormalities (pooled OR: 1.25 with 95%CI: 1.20, 1.30), anomalies of the kidney and urinary tract (pooled OR: 1.14 with 95%CI: 1.02, 1.27), anomalies of digestive system (pooled OR: 1.11 with 95%CI: 1.01, 1.21), abdominal birth defects (pooled OR: 1.33 with 95%CI: 1.16, 1.53) and musculoskeletal malformations (pooled OR: 1.44 with 95%CI: 1.32, 1.56).
Conclusions: SSRIs and SNRIs have various teratogenic risks. Clinicians must consider risk-benefit ratios and patient history when prescribing medicines.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Huang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919)
BMJ. 2014 Jan 14;348:f6932. (PMID: 24429387)
Congenit Anom (Kyoto). 2017 May;57(3):72-78. (PMID: 27878857)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
Neurosci Biobehav Rev. 2016 Jul;66:54-60. (PMID: 27126289)
JAMA Psychiatry. 2023 Jun 1;80(6):539-547. (PMID: 37074698)
Reprod Toxicol. 2019 Mar;84:108-113. (PMID: 30639403)
PLoS One. 2016 Dec 1;11(12):e0165122. (PMID: 27906972)
Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. (PMID: 19740668)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
Front Cell Neurosci. 2015 Jan 13;8:465. (PMID: 25628539)
Clin Ther. 2007 May;29(5):918-926. (PMID: 17697910)
Br J Clin Pharmacol. 2016 Apr;81(4):589-604. (PMID: 26613360)
N Engl J Med. 2014 Jun 19;370(25):2397-407. (PMID: 24941178)
Orphanet J Rare Dis. 2017 Jun 20;12(1):116. (PMID: 28633635)
BMJ. 2015 Apr 17;350:h1798. (PMID: 25888213)
J Pediatr. 2022 Jan;240:79-86.e1. (PMID: 34508749)
Psychiatry Res. 2021 Jun;300:113912. (PMID: 33836471)
Br J Clin Pharmacol. 2008 Nov;66(5):695-705. (PMID: 18754846)
Iran J Basic Med Sci. 2018 Apr;21(4):417-421. (PMID: 29796227)
Obstet Gynecol. 2021 Oct 1;138(4):633-646. (PMID: 34623076)
Endocrine. 2004 Jul;24(2):155-9. (PMID: 15347842)
Obstet Gynecol. 2011 Jul;118(1):111-120. (PMID: 21646927)
Biometrics. 2000 Jun;56(2):455-63. (PMID: 10877304)
J Clin Psychopharmacol. 2012 Apr;32(2):186-94. (PMID: 22367660)
Arch Womens Ment Health. 2020 Apr;23(2):207-214. (PMID: 30982086)
Am J Obstet Gynecol. 2015 Jun;212(6):795.e1-795.e12. (PMID: 25637841)
Birth Defects Res A Clin Mol Teratol. 2009 Oct;85(10):837-41. (PMID: 19691085)
Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1160-1169. (PMID: 27193296)
Neurochem Res. 2012 Nov;37(11):2496-512. (PMID: 22717696)
JAMA Psychiatry. 2020 Dec 1;77(12):1246-1255. (PMID: 32777011)
Epidemiology. 2014 Nov;25(6):859-65. (PMID: 25171134)
BMC Med. 2018 Nov 12;16(1):205. (PMID: 30415641)
BMJ. 2020 Feb 19;368:m237. (PMID: 32075794)
Acta Psychiatr Scand. 2022 Jan;145(1):6-28. (PMID: 34486740)
Natl Vital Stat Rep. 2022 Sep;71(5):1-18. (PMID: 36190428)
Obstet Gynecol. 2023 Sep 1;142(3):652-659. (PMID: 37535962)
J Cardiovasc Pharmacol. 2017 Aug;70(2):119-127. (PMID: 28459713)
Epidemiology. 2006 Nov;17(6):701-4. (PMID: 17028507)
J Biochem Mol Toxicol. 2022 Jul;36(7):e23062. (PMID: 35363936)
Drug Saf. 2021 Mar;44(3):291-312. (PMID: 33354752)
BMJ. 2009 Sep 23;339:b3569. (PMID: 19776103)
Am J Psychiatry. 2001 Oct;158(10):1728-30. (PMID: 11579012)
Mol Psychiatry. 2016 May;21(5):656-64. (PMID: 26347317)
Clin Epidemiol. 2010 Aug 09;2:29-36. (PMID: 20865100)
Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):783-93. (PMID: 23620412)
BJOG. 2014 Nov;121(12):1471-81. (PMID: 24612301)
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):942-51. (PMID: 23733623)
J Clin Psychiatry. 2016 Jan;77(1):e36-42. (PMID: 26845280)
Neurotox Res. 2022 Oct;40(5):1174-1190. (PMID: 35819590)
Aust N Z J Psychiatry. 2013 Nov;47(11):1002-12. (PMID: 23761574)
J Affect Disord. 2020 Mar 1;264:82-89. (PMID: 31846905)
Birth Defects Res A Clin Mol Teratol. 2014 Dec;100(12):912-23. (PMID: 25308507)
PLoS Med. 2021 Nov 22;18(11):e1003851. (PMID: 34807906)
Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S81-6. (PMID: 10523062)
J Clin Endocrinol Metab. 2000 Mar;85(3):1277-86. (PMID: 10720076)
Birth Defects Res. 2023 Apr 1;115(6):583-594. (PMID: 36734416)
Pharmacotherapy. 2013 Jul;33(7):693-700. (PMID: 23744675)
PLoS One. 2008 Jul 23;3(7):e2782. (PMID: 18716672)
Am J Obstet Gynecol. 2005 Dec;193(6):2004-9. (PMID: 16325604)
Congenit Anom (Kyoto). 2020 Nov;60(6):180-188. (PMID: 32673440)
N Engl J Med. 2007 Jun 28;356(26):2684-92. (PMID: 17596602)
J Clin Epidemiol. 2005 Sep;58(9):894-901. (PMID: 16085192)
Paediatr Perinat Epidemiol. 2022 Nov;36(6):782-791. (PMID: 35437856)
Cleve Clin J Med. 2020 May;87(5):273-277. (PMID: 32357982)
PLoS One. 2015 Oct 02;10(10):e0139719. (PMID: 26431045)
BMC Pregnancy Childbirth. 2014 Sep 25;14:333. (PMID: 25258023)
J Clin Psychopharmacol. 2017 Jun;37(3):332-340. (PMID: 28383363)
N Engl J Med. 2007 Jun 28;356(26):2675-83. (PMID: 17596601)
Birth Defects Res A Clin Mol Teratol. 2016 Dec;106(12):1044-1055. (PMID: 27384265)
PLoS One. 2022 Jul 22;17(7):e0269855. (PMID: 35867704)
Pediatr Res. 2013 Mar;73(3):286-93. (PMID: 23232669)
BMJ Open. 2017 Jan 12;7(1):e013372. (PMID: 28082367)
CNS Drugs. 2015 Mar;29(3):245-52. (PMID: 25708711)
Birth Defects Res A Clin Mol Teratol. 2013 Jan;97(1):28-35. (PMID: 23281074)
Epidemiology. 2018 Sep;29(5):721-728. (PMID: 29863532)
BJOG. 2021 Nov;128(12):1949-1957. (PMID: 34036715)

0 (Selective Serotonin Reuptake Inhibitors)
0 (Serotonin and Noradrenaline Reuptake Inhibitors)
X4W3ENH1CV (Norepinephrine)
333DO1RDJY (Serotonin)

Date Created: 20231129 Date Completed: 20231201 Latest Revision: 20231201

20240628

PMC10686472

10.1371/journal.pone.0294996

38019759